Analyst Conference Summaries

Biotechnology Investor Aids

Bioverativ
BIVV

conference date: October 27, 2017 @ 5:00 AM Pacific Time

Bioverativ Target Raised on 10-K Data [Seeking Alpha, March 27, 2017]

Bioverativ Should have a Strong Launch [January 10, 2017 @ Seeking Alpha]

Note: BIVV started trading on February 1, 2017.

2017
 
May 4, 2017
August 3, 2017
Oct. 27, 2017
 

Bioverativ (BIVV) is a commercial-stage biotechnology company specializing in hemophilia therapies and developing therapies for other blood disorders. It was spun off from Biogen (BIIB).

Bioverativ web site


 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMD
 AMGN
 BIIB
 BIND
 CLDX
 CELG
 EPZM
 GILD
 GLYC
 INO
 INTC
 ISRG
 JUNO
 MACK
 MCHP
 MYL.
 NVDA
 PLX
 REGN
 SGEN
 XLNX
 XLRN
 

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2017 William P. Meyers